Catheter-related septic thrombophlebitis of the great central veins successfully treated with low-dose streptokinase thrombolysis and antimicrobials.
BACKGROUND
Septic thrombophlebitis is an iatrogenic life-threatening disease associated with use of central venous devices and intravenous (IV) therapy. In cancer patients receiving chemotherapy, vein resection or surgical thrombectomy in large central venous lines is time-consuming, can delay administration of chemotherapy, and therefore can compromise tumor control. Experience with thrombolysis has been published for catheter-related thrombosis but for septic thrombosis, this experience is scarce.


RESULTS
We describe three patients with cancer and septic thrombophlebitis of central veins caused by Staphylococcus aureus treated with catheter removal, thrombolysis, and intravenous (IV) antibiotics. In our reported cases, an initial bolus of 250,000 international units (IU) of streptokinase administered during the first h followed by an infusion of 20,000-40,000 IU/h for 24-36 h through a proximal peripheral vein was sufficient to dissolve the thrombus. After thrombolysis and parenteral antibiotic for 4-6 weeks the septic thrombosis due to Staphylococcus aureus solved in all cases. No surgical procedure was needed, and potential placement of a catheter in the same vein was permitted.


CONCLUSIONS
Thrombolysis with streptokinase solved symptoms, cured infection, prevented embolus, and in all cases achieved complete thrombus lysis, avoiding permanent central-vein occlusion.
Volkow
Patricia
P
Mexican National Institute of Cancer (INCan), Mexico City, Mexico.
Cornejo-Juárez
Patricia
P
Mexican National Institute of Cancer (INCan), Mexico City, Mexico.
Arizpe-Bravo
Ana Berta
AB
Mexican National Institute of Cancer (INCan), Mexico City, Mexico.
García-Méndez
Jorge
J
Mexican National Institute of Cancer (INCan), Mexico City, Mexico.
Baltazares-Lipp
Enrique
E
Mexican National Institute of Respiratory Diseases (INER), Mexico City, Mexico.
Pérez-Padilla
Rogelio
R
Mexican National Institute of Respiratory Diseases (INER), Mexico City, Mexico.